For example, a 69-year-old female with advanced pancreatic cancer harboring a germline ATM frameshift alteration treated with two lines of prior therapy (chemotherapy and immunotherapy) had a 50% decline in cancer antigen 19-9 (CA-19-9) at week 9 and a gradual decline in TLs, eventually resulting in a RECIST 1.1 cPR at week 54 (Fig. 2c). This evidence concerns the gene ATM and cancer.